Laquinimod sodium is under clinical development by Active Biotech and currently in Phase I for Non-infectious Uveitis. According to GlobalData, Phase I drugs for Non-infectious Uveitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Laquinimod sodium LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Laquinimod sodium overview

Laquinimod sodium (ABR-215062) is under development for the treatment of non-infectious non-anterior uveitis and wet age-related macular degeneration. It is administered by oral and topical route. Laquinimod targets nuclear factor kappa B and Aryl Hydrocarbon Receptor (AHR). It was also under development for Crohn's disease, relapsing-remitting multiple sclerosis, Huntington disease, systemic lupus erythematosus patients with lupus arthritis, primary progressive multiple sclerosis, lupus nephritis and relapsing-remitting multiple sclerosis (RRMS).

Active Biotech overview

Active Biotech is a biotechnology company that focuses on the development of therapeutics in the field of cancer, inflammatory eye disorders and neurodegenerative diseases. The company’s pipeline products include naptumomab for the treatment of solid tumors and lung cancer; tasquinimod for multiple myeloma; and laquinimod for the Uveitis. The portfolio comprises of antibody-based immunotherapy and small, orally active immunomodulatory molecules. It has partnerships with NeoTX Therapeutics Ltd and with the Perelman School of Medicine, University of Pennsylvania. The company’s products have patents and patent applications in markets of the US, Japan, and Europe. Active Biotech is headquartered in Lund, Sweden.

For a complete picture of Laquinimod sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.